Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms
Journal of Obesity · 15.10.2018 · 2018 · 1-5
DOI: 10.1155/2018/8532602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obesity, erschienen am 15.10.2018. Verfasst von Scott V Monte und 3 weiteren Autor:innen. Beteiligte Einrichtung: University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA. Hauptthemen laut MEDLINE: Gastrectomy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sleeve gastrectomy (SG) has become the primary bariatric surgery procedure in the U.S. Over 50% of people presenting for surgery have psychiatric diagnoses. The study purpose was to evaluate change in anxiety and depression symptoms and medication use after SG.
Methods
Subjects completing SG with a diagnosis of anxiety and/or depression treated with medication were retrospectively identified from the electronic medical record (EMR) of Synergy Bariatrics, a department of the Erie County Medical Center. Phone outreach was made to complete seven-point global impression of change scale classifying symptom improvement or worsening in the 3- to 6-month postoperative period. Improvement or worsening was defined as either all reported symptoms improving or worsening or ≥1 improving or worsening while remaining unchanged. If ≥1 symptom improved and worsened, it was classified as mixed. No change required the same profile before and after surgery. Medication, dose, and changes were identified by EMR, verified during interview and classified as no change, discontinued, decreased, or increased.
Results
59 subjects completed the interview. 21 subjects were diagnosed with anxiety. 13 (62%) had no change in therapy and 5 (24%) decreased. Symptoms improved in 12 (57%), worsened in 3 (14%), and mixed in 5 (24%). When symptoms improved, the same dose was present in 7/12 (58%) and dose decreased in 3 (25%). 51 subjects were diagnosed with depression. 32 (63%) had no change in therapy, 11 (21%) discontinued, and 4 (8%) decreased. Symptoms improved in 34 (67%), mixed in 10 (20%), worsened in 4 (8%), and unchanged in 3 (6%). When symptoms improved, the same regimen and dose was present in 21/34 cases (62%) and discontinued in 9 (26%).
Conclusion
Anxiety symptoms improved in >50% of subjects at predominantly the same or reduced dosage. Depression symptoms improved in 67% and commonly without therapy change. These data suggest evidence that patients undergoing SG while on medication for anxiety or depression may have early symptom improvement on the same or lessened dosage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA.
- Synergy Bariatrics, A Department of ECMC, University at Buffalo School of Medicine, Buffalo, NY 14214, USA.
ORCID-Profile: Scott V Monte
Zitieren
APA
Monte, S. V., Russo, K. M., Mustafa, E., & Caruana, J. A. (2018). Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms. Journal of Obesity, 2018, 1-5. https://doi.org/10.1155/2018/8532602
Vancouver
Monte SV, Russo KM, Mustafa E, Caruana JA. Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms. Journal of Obesity. 2018;2018:1-5. doi:10.1155/2018/8532602
BibTeX
@article{Monte2018,
author = {Monte, Scott V and Russo, Kristen M and Mustafa, Esra and Caruana, Joseph A},
title = {Impact of Sleeve Gastrectomy on Psychiatric Medication Use and Symptoms},
journal = {Journal of Obesity},
year = {2018},
volume = {2018},
pages = {1--5},
doi = {10.1155/2018/8532602}
}
EUVIMED